Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

60Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs.

Cite

CITATION STYLE

APA

Gara, S. K., Lack, J., Zhang, L., Harris, E., Cam, M., & Kebebew, E. (2018). Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-06366-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free